News articles about Bruker (NASDAQ:BRKR) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bruker earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.0744535228934 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Bruker Appoints Gerald Herman as Interim Chief Financial Officer (finance.yahoo.com)
- Bruker names interim CFO (seekingalpha.com)
- Bruker and Evosep Announce New Integrated Clinical Research Proteomics Solution to Quantify Over a Thousand Proteins in Five Minutes (finance.yahoo.com)
- Bruker (BRKR) Down 9.3% Since Earnings Report: Can It Rebound? (finance.yahoo.com)
- Bruker Co. (BRKR) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
Shares of Bruker (BRKR) opened at $30.04 on Thursday. The firm has a market cap of $4,670.00, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 2.04 and a beta of 1.15. Bruker has a twelve month low of $21.83 and a twelve month high of $36.53. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 23rd. Stockholders of record on Tuesday, March 6th will be given a dividend of $0.04 per share. The ex-dividend date is Monday, March 5th. This represents a $0.16 annualized dividend and a dividend yield of 0.53%. Bruker’s dividend payout ratio is currently 17.20%.
Several research firms recently issued reports on BRKR. BidaskClub cut shares of Bruker from a “buy” rating to a “hold” rating in a report on Saturday, February 10th. Morgan Stanley cut their price target on shares of Bruker from $35.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, February 9th. Leerink Swann upped their price target on shares of Bruker from $32.00 to $34.00 and gave the company a “market perform” rating in a report on Friday, February 9th. Zacks Investment Research cut shares of Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, BTIG Research assumed coverage on shares of Bruker in a report on Friday, January 5th. They set a “buy” rating and a $42.00 target price on the stock. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $32.62.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.